Advanced Lewis Lung Carcinoma Cured by Tiazofurin as a System to Study Delayed Hemopoietic Effects of Cancer
- 1 January 1988
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 6 (6) , 681-686
- https://doi.org/10.3109/07357908809078035
Abstract
Lewis lung carcinoma (LLC) induces a range of hemopoietic alterations in its murine hosts including progressive anemia, thrombocytopenia, splenomegaly, neutrophila, and marrow and splenic myeloid hyperplasia. Concentrations of both pluripotent and commited marrow hemopoietic progenitors is increased and the cycling fraction of granulyocyte-macrophage progenitors is accelerated. We have developed a way to study whether these hemopoietic effects becomes long-term consequences of cancer, using LLC-bearing mice wtih advanced tumor treated with the antineoplastic agent tiazofurin, 2-.beta.-D-ribofuranosyl-thriazole-4-carboxyamide, NSC 286193 (TZ). LLC mice were treated with a single dose of TZ either 150, 300, or 600 mg/kg, intraperitoneally on day 6 posttumor implant when lung metastases are present and all hemopoietic effects of the tumor are recognizable. Even a single dose of 150 mg/kg of TZ produced a significant survival advantage, and 600 mg/kg resulted in 30% of the animals remaining disease free during a 5-month follow-up. A 6-week treatment schedule was devised, administering TZ intraperitoneally, 600 mg/kg, weekly beginning on day 6. In this group, median survival was not reached after 9 months of follow-up. The only evidence of myelotoxicity produced by intermittent administration of TZ was a mild anemia which was fully reversible 2 weeks after discontinuance of the drug. No difference in white blocked cell count, differential count, or platelet count was detected in tumor bearers and controls treated with TZ. Both pluripotent and committed marrow hemopoietic precursors remained unchanged in TZ-LLC, TZ-controls and untreated controls throughout treatment and 2 weeks thereafter. This study demonstrates that TZ-cured LLC mice are suitable to explore late hemopoietic effects of cancer.This publication has 20 references indexed in Scilit:
- Review: Hemopoietic Alterations of CancerThe Lancet Healthy Longevity, 1985
- Studies on the mechanism of action of 2-β-d-ribofuranosylthiazole-4-carboxamide (NSC 286193)-IIBiochemical Pharmacology, 1982
- Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-β-d-ribofuranosylthiazole-4-carboxamide NSC 286193)Biochemical Pharmacology, 1982
- The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory propertiesBiochemical Pharmacology, 1982
- 2-.beta.-D-ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastasesJournal of Medicinal Chemistry, 1982
- Transient nature of early haematopoietic spleen coloniesNature, 1982
- Characterization of a primitive erythropoietic progenitor found in mouse marrow before and after several weeks in cultureBlood, 1979
- Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: Studies of three erythropoietic colony responses in cultureJournal of Cellular Physiology, 1976
- THE GROWTH OF MOUSE BONE MARROW CELLS IN VITROImmunology & Cell Biology, 1966
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958